- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01964976
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Study Overview
Status
Conditions
Detailed Description
This is a special drug use surveillance on long-term use of alogliptin with a 1-year (12-month) observational period, designed to investigate the safety and efficacy of long-term combination therapy with alogliptin and biguanides in participants with type 2 diabetes mellitus in the routine clinical setting.
Participants diagnosed with type 2 diabetes mellitus who responded inadequately to treatment with biguanides in addition to diet therapy and exercise therapy will be enrolled. The planned sample size is 1,000.
The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tokyo, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants who did not adequately respond to the following treatment • Treatment with biguanides in addition to diet therapy and exercise therapy
Exclusion Criteria:
Participants contraindicated for Nesina
- Participants with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus [these participants require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of Nesina is not appropriate].
- Participants with severe infection, pre- or post-operative patients, or patients with serious traumatic injury [blood glucose control by insulin injection is desirable for these participants, and hence use of Nesina is not appropriate].
- Participants with a history of hypersensitivity to any ingredient of Nesina.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Alogliptin + Biguanides
All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Reporting One or More Adverse Drug Reactions
Time Frame: Baseline up to 12 months
|
Adverse drug reactions are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment.
AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.
The safety analysis was planned to be assessed in alogliptin + biguanides and alogliptin + other arm separately.
|
Baseline up to 12 months
|
Number of Participants Reporting One or More Serious Adverse Drug Reactions
Time Frame: Baseline up to 12 months
|
Serious adverse drug reactions are defined as serious adverse events (SAEs) which are in the investigator's opinion of causal relationship to the study treatment.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
The safety analysis was planned to be assessed in alogliptin + biguanides and alogliptin + other arm separately.
|
Baseline up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Time Frame: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Percentage of Participants of Achieving Objective Glycemic Control
Time Frame: Baseline and final assessment (up to Month 12)
|
The rate of achieving objective glycemic control in HbA1c level, was calculated at 12 month or final visit (last visit for a participant in the study, up to Month 12).
Glycemic control was measured as <8.0%, <7.0%, and <6.0% of glycosylated hemoglobin.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline and final assessment (up to Month 12)
|
Change From Baseline in Fasting Blood Glucose
Time Frame: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change between the fasting blood glucose value collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of the biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Change From Baseline in Fasting Insulin Level
Time Frame: Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
The change between the fasting insulin value collected at 1 month, 3 months, 6 months, 12 months or final visit (last visit for a participant in the study, up to Month 12) relative to baseline.
The efficacy analysis was planned to be assessed in the total alogliptin arm irrespective of biguanide treatment.
|
Baseline, Months 1, 3, 6, 12, and final assessment (up to Month 12)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 121-014
- JapicCTI-132282 (Registry Identifier: JapicCTI)
- JapicCTI-R150790 (Registry Identifier: JapicCTI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surveillance
-
Natural Immune Systems IncRecruitingImmune SurveillanceUnited States
-
Chulalongkorn UniversityUnknownSurveillance Protocol BiopsyThailand
-
Renmin Hospital of Wuhan UniversityNot yet recruitingArtificial Intelligence | SurveillanceChina
-
Renmin Hospital of Wuhan UniversityJiangmen Central HospitalNot yet recruitingArtificial Intelligence | SurveillanceChina
-
Ohio State University Comprehensive Cancer CenterRecruitingCancer SurveillanceUnited States
-
Natural Immune Systems IncRecruitingImmune SurveillanceUnited States
-
CargillNatural Immune Systems IncCompleted
-
Chinese University of Hong KongUnknownSurveillance ColonoscopyHong Kong
-
Borland-Groover ClinicValley Medical Products, LLC is paying for the study and is the sponsor....CompletedColonoscopy | Screening Colonoscopy | Surveillance ColonoscopyUnited States
-
Boston Scientific CorporationICON plcCompletedPost Market Surveillance Study Following Clinical RoutineGermany, Finland